Merck Sharp & Dohme Corp. - Recruiting 12 years or older. - A One-year Placebo-Controlled Study Evaluating the Efficacy and Safety of the House Dust Mite Sublingual Allergen Immunotherapy Tablet (SCH 900237/MK 8237) in Children and Adult Subjects With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis With or Without Asthma (Protocol No. P05607/001-00).
Merck Sharp & Dohme Corp. - Recruiting 18 years to 55 years. - A Two Part, Randomized Clinical Trial to Study Biomarkers of MK-8237 (SCH 900237) Treatment in Subjects With House Dust Mite Induced Allergic Rhinitis or Rhinoconjunctivitis.
Ahn-Gook Pharmaceuticals Co.,Ltd - Recruiting 12 years or older. - A 4 Week Multicenter, Double-blind, Randomized, Placebo-controlled Study to Assess the Efficacy and Safety of AGR Tablet in the Treatment of Perennial Allergic Rhinitis in Korean : a Phase III Clinical Trial Bridging Study.
AGR tablet; Placebo (for AGR tablet and/or Active Comparator); Active Comparator
Circassia Limited - Recruiting 18 years to 65 years. - A Multi-Centre, Double-Blind, Randomised, Placebo-Controlled Parallel-Group Study to Assess the Safety and Tolerability of Ragweed-SPIRE in Subjects With Asthma and Ragweed-Induced Rhinoconjunctivitis.
Circassia Limited - Recruiting 18 years to 65 years. - A Double-Blind, Randomised, Placebo-Controlled Study to Evaluate Four Dose Regimens of Ragweed-SPIRE in Ragweed Allergic Subjects Following Challenge With Ragweed Allergen in an Environmental Exposure Chamber.
West Penn Allegheny Health System - Recruiting 12 years to 15 years. - A Study Evaluating the Effect of Omnaris Nasal Spray 200 mcg QD & Alvesco Inhalation Aerosol 80 BID vs Beconase AQ Nasal Spray 168 mcg BID & QVAR Inhalation Aerosol 40 mcg BID vs Placebo Nasal Spray QD & Placebo Inhalation Aerosol BID on Short Term Growth in Pediatric Subjects With Mild Asthma & Allergic Rhinitis.
Imperial College London - Recruiting 18 years to 65 years. - Randomised Placebo-controlled Study of Grass Pollen Allergen Immunotherapy Tablet (AIT) for Seasonal Rhinitis: Time Course of Nasal, Cutaneous and Immunological Outcomes.
PharmaKing - Recruiting 20 years to 45 years. - A Randomized, Open-label, Single-Dose, 2-Treatment, 2-Way, 2-Period Crossover Study to Compare the Safety and the Pharmacokinetic Characteristics of MKT-N2 (Montelukast) and Singulairr (Montelukast Sodium) Tablet 10mg in Healthy Male Korean Subjects.
GlaxoSmithKline - Recruiting 2 years or older. - An Open Label, Multi-centre, Non-interventional Post-marketing Surveillance (PMS) to Monitor the Safety and Effectiveness of Avamysr Administered in Korean Patients According to the Prescribing Information.
Novartis - Recruiting 18 years to 65 years. - A Randomized, Double-blind, Placebo-controlled Three-period Incomplete Cross Over Study to Compare the Efficacy of QAW039 Alone and in Combination With Montelukast in Patients With Allergic Rhinitis Using an Environmental Exposure Chamber.
Medical Universtity of Lodz - Recruiting 6 years to 18 years. - Assessment of Effectiveness and Safety of Annual Sublingual Immunotherapy in Children With Bronchial Asthma and/or Allergic Rhinitis Allergic to House Dust Mites.
sublingual house dust mites allergen extract; placebo in sublingual applicator